Cormedix Stock In The News

CRMD Stock  USD 10.47  0.09  0.87%   
Our overall analysis of CorMedix's news coverage and content from conventional and social sources shows investors' bearish mood towards CorMedix. The specific impact of CorMedix news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of CorMedix's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using CorMedix headlines in addition to utilizing other, more conventional financial analysis modules. Check out CorMedix Backtesting and CorMedix Hype Analysis.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

CorMedix Today Top News and Investor Outlook

Yahoo News
CorMedix Inc. Added to Nasdaq Biotechnology Index
https://finance.yahoo.com/news/cormedix-inc-added-nasdaq-biotechnology-133000792.html
 Bullish
Yahoo News
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
https://finance.yahoo.com/news/biotech-budget-7-stocks-under-165418993.html
 Bullish
Macroaxis News: globenewswire.com
CorMedix Inc. Announces FDA Approval of ...
https://www.globenewswire.com/news-release/2023/11/15/2781334/0/en/CorMedix-Inc-Announces-FDA-Approval-of-DefenCath-to-Reduce-the-Incidence-of-Catheter-Related-Bloodstream-Infections-in-Adult-Hemodialysis-Patients.html
 Neutral
Macroaxis News: globenewswire.com
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2023/11/14/2780500/0/en/CorMedix-Inc-Reports-Third-Quarter-and-Nine-Month-2023-Financial-Results-and-Provides-Business-Update.html
 Bullish
Macroaxis News: globenewswire.com
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
https://www.globenewswire.com/news-release/2023/11/02/2772311/0/en/CorMedix-Inc-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-a-Corporate-Update-on-November-14-2023.html
 Bullish
Macroaxis News: globenewswire.com
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
https://www.globenewswire.com/news-release/2023/10/11/2758357/0/en/CorMedix-Inc-Announces-Abstract-Presentation-at-Upcoming-IDWeek-Conference.html
 Neutral
Macroaxis News: globenewswire.com
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/26/2749521/0/en/CorMedix-Inc-to-Present-at-the-Cantor-Fitzgerald-Global-Healthcare-Conference.html
 Bullish
Yahoo News
15 Penny Stocks with Biggest Upside
https://finance.yahoo.com/news/15-penny-stocks-biggest-upside-145437198.html
 Neutral
Macroaxis News: globenewswire.com
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
https://www.globenewswire.com/news-release/2023/09/08/2740086/0/en/CorMedix-Inc-Announces-Publication-of-Phase-3-LOCK-IT-100-Study-Data-in-the-Clinical-Journal-of-The-American-Society-of-Nephrology.html
 Bullish
Macroaxis News: globenewswire.com
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
https://www.globenewswire.com/news-release/2023/09/06/2738409/0/en/CorMedix-Inc-to-Present-at-the-H-C-Wainwright-Annual-Global-Investment-Conference.html
 Bullish

CorMedix Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide CorMedix and other traded companies coverage with news coverage. We help investors stay connected with CorMedix headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on CorMedix Stock performance. Please note that trading solely based on the CorMedix hype is not for everyone as timely availability and quick action are needed to avoid losses.
CorMedix's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help CorMedix investors visualize upcoming and past events in order to time the market based on CorMedix noise-free hype analysis.
CorMedix stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the CorMedix earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about CorMedix that are available to investors today. That information is available publicly through CorMedix media outlets and privately through word of mouth or via CorMedix internal channels. However, regardless of the origin, that massive amount of CorMedix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CorMedix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CorMedix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CorMedix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CorMedix alpha.

CorMedix Largest EPS Surprises

Earnings surprises can significantly impact CorMedix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.18-0.2-0.0211 
2024-05-09
2024-03-31-0.28-0.250.0310 
2022-03-29
2021-12-31-0.23-0.20.0313 
2021-03-30
2020-12-31-0.22-0.190.0313 
2020-11-05
2020-09-30-0.25-0.220.0312 
2020-03-16
2019-12-31-0.24-0.210.0312 
View All Earnings Estimates

CorMedix Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to CorMedix Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
news
13th of March 2025
CorMedix Shares Down 7.4 percent Heres Why
at thelincolnianonline.com 
Macroaxis News
5th of March 2025
Acquisition by Duncan Gregory Scott of 25000 shares of CorMedix subject to Rule 16b-3
at MacroaxisInsider 
Simply Wall St News at Macroaxis
26th of February 2025
While shareholders of CorMedix are in the black over 1 year, those who bought a week ago a...
at simplywall.st 
Gurufocus Stories at Macroaxis
7th of February 2025
Rosalind Advisors, Inc. Expands Stake in InspireMD Inc.
at gurufocus.com 
Yahoo News
22nd of January 2025
Were Hopeful That CorMedix Will Use Its Cash Wisely
at finance.yahoo.com 
Simply Wall St News at Macroaxis
17th of January 2025
Heres Why Were Not Too Worried About CorMedixs Cash Burn Situation
at simplywall.st 
Macroaxis News
10th of January 2025
Disposition of 5790 shares by Hurlburt Elizabeth of CorMedix at 11.19 subject to Rule 16b-...
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
7th of January 2025
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Upda...
at gurufocus.com 
Macroaxis News
6th of January 2025
Acquisition by Erin Mistry of 62500 shares of CorMedix subject to Rule 16b-3
at MacroaxisInsider 
zacks News
27th of December 2024
Is CorMedix Stock Outpacing Its Medical Peers This Year
at zacks.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CorMedix in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CorMedix's short interest history, or implied volatility extrapolated from CorMedix options trading.
When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:
Check out CorMedix Backtesting and CorMedix Hype Analysis.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Revenue Per Share
0.212
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.38)
Return On Equity
(0.65)
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.